Back

Drug-coated balloon versus drug-eluting stent for de novo culprit lesion in acute coronary syndromes: a report from nationwide registry in japan

1 September 2024 (11:00 - 11:50)
Organised by: Logo
Congress Presentation Part of: Improving techniques and devices for better outcomes in percutaneous coronary interventions Devices ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Assistant Professor Tomonori Takahashi

Tokushima University Hospital, Tokushima (Japan)

7 More presentations in this session

Presentation thumbnail
A retrospective study on real world, 2-stent left main bifurcation PCI using DK crush technique with IVUS guidance - a single center experience
Doctor K. Kaniappan (Kuala Lumpur, MY)
Abstract Slides Video
Presentation thumbnail
OSDOKINA crush technique for the management of side branch ostial lesion ISTANBOL study
Associate Professor I. Donmez (Bolu, TR)
Abstract Slides Video
Presentation thumbnail
Side branch interventions late after MFM implantation
Doctor P. Polomski (Sofia, BG)
Abstract Slides Video
Presentation thumbnail
Safety and feasibility of drug eluting and perfusion therapy for left main disease: JDEPTH-LM pilot study
Doctor T. Warisawa (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Biolimus A9 DEB for the Treatment of In-Stent Restenosis. 1-year outcomes of the REFORM trial.
Doctor R. Durand (Dublin, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Improving techniques and devices for better outcomes in percutaneous coronary interventions

The Event

Event poster

ESC Congress 2024

1 September 2024 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Two-year outcomes of drug-coated balloon only strategy for de novo lesions in large coronary vessels
thumbnail
Congress Presentation
Drug-coated balloon versus drug-eluting stent revascularization in the treatment of de novo acute myocardial infarction
thumbnail
Congress Presentation
Drug-coated ballons vs drug-eluting stent in de novo coronary lesions, a propensity-score matched cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources